erenumab (aimovig) is the first of four new migraine drugs in the pipeline that target calcitonin gene-related peptide (cgrp), a molecule that's produced in nerve cells of the
.anjali shrivastava covers academics and administration. contact her at
.
the youngest claimant was aged 20, and the eldest aged 89, while the average policy duration at claim stage was 10 years.
.
: "arise: a phase 3 randomized trial of erenumab for episodic migraine."
.
.